Essential Thrombocythemia

8
Pipeline Programs
4
Companies
7
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
1
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 5 programs with unclassified modality

On Market (1)

Approved therapies currently available

PharmaEssentia
BESREMIApproved
ropeginterferon alfa-2b
PharmaEssentia
Interferon alfa-2b [EPC]subcutaneous2021

Competitive Landscape

4 companies ranked by most advanced pipeline stage

PharmaEssentia
PharmaEssentiaMA - Burlington
2 programs
1
1
1
Ropeginterferon alfa-2bPhase 31 trial
Ropeginterferon alfa-2b-njftPhase 21 trial
Active Trials
NCT05482971Active Not RecruitingEst. Mar 2027
NCT04285086Active Not RecruitingEst. Aug 2029
M&
Merck & Co.RAHWAY, NJ
3 programs
2
1
BomedemstatPhase 3Small Molecule1 trial
BomedemstatPhase 2Small Molecule1 trial
IMG-7289Phase 21 trial
Active Trials
NCT04254978CompletedEst. Mar 2023
NCT04262141Active Not RecruitingEst. Oct 2027
NCT06079879Recruiting340Est. Aug 2028
Novartis
NovartisBASEL, Switzerland
1 program
1
AnagrelidePhase 2/31 trial
Active Trials
NCT02962388Terminated13Est. Jun 2021
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
Allogeneic Hematopoietic Stem Cell TransplantationPhase 1/21 trial
Active Trials
NCT03878199Completed12Est. Feb 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Merck & Co.Bomedemstat
PharmaEssentiaRopeginterferon alfa-2b
NovartisAnagrelide
PharmaEssentiaRopeginterferon alfa-2b-njft
Merck & Co.IMG-7289
Merck & Co.Bomedemstat
Jazz PharmaceuticalsAllogeneic Hematopoietic Stem Cell Transplantation

Clinical Trials (7)

Total enrollment: 365 patients across 7 trials

NCT06079879Merck & Co.Bomedemstat

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Start: Dec 2023Est. completion: Aug 2028340 patients
Phase 3Recruiting
NCT04285086PharmaEssentiaRopeginterferon alfa-2b

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Start: Aug 2020Est. completion: Aug 2029
Phase 3Active Not Recruiting
NCT02962388NovartisAnagrelide

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Start: Jan 2017Est. completion: Jun 202113 patients
Phase 2/3Terminated
NCT05482971PharmaEssentiaRopeginterferon alfa-2b-njft

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Start: Sep 2022Est. completion: Mar 2027
Phase 2Active Not Recruiting
NCT04262141Merck & Co.IMG-7289

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Start: Oct 2020Est. completion: Oct 2027
Phase 2Active Not Recruiting
NCT04254978Merck & Co.Bomedemstat

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Start: Sep 2020Est. completion: Mar 2023
Phase 2Completed
NCT03878199Jazz PharmaceuticalsAllogeneic Hematopoietic Stem Cell Transplantation

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Start: Feb 2019Est. completion: Feb 202512 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 365 patients
4 companies competing in this space